久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

比利時Galapagos NV?
Galapagos目標發現平臺，提供新的出發點治療藥物和抗體，從而解決了業界的創新，疾病修飾藥物的需要。Galapagos是為更好的藥物利用這個平臺的疾病領域有一個明確的需要。該公司的產品組合主要包括新的模式，對行動藥物在骨關節疾病以及癌癥的轉移，惡病質和孤兒疾病的方案。為使方案的廣泛產品組合的進展，建立了Galapagos在特定疾病領域的大型制藥公司的風險共享合作關系。通過與MorphoSys的聯盟，也正在開發中的Galapagos骨與關節疾病的抗體療法。

Galapagos的服務部門，其中包括BioFocus和來自阿根最近收購的服務業務，提供了一個目標到藥物發現的產品和服務的全部套件，制藥，生物技術和病人的基礎 - 包括目標和藥物發現通過對前交貨臨床候選人。

Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry's need for innovative, disease-modifying medicines. Galapagos is exploiting this platform in disease areas for which there is a clear need for better medicines. The Company's product portfolio consists mainly of new mode-of-action drugs in bone and joint diseases as well as programs in cancer metastasis, cachexia and orphan diseases. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases.

Galapagos' service division, which includes BioFocus and the recently acquired service operations from Argenta, offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates.

Galapagos was founded in 1999 as a joint venture between Crucell and Tibotec. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs with service activities. In 2002 the Company raised €23.4 million in a private placement. In May 2005, the Company raised €22.4 million through an initial public offering on Euronext Brussels and Amsterdam (ticker symbol: GLPG). Galapagos raised an additional €60 million through private placements in 2006 and 2009 and a further €4.4 million through an equity investment by GlaxoSmithKline in 2007. Through a Level 1 ADR listing in the US, Galapagos is traded on the U.S. OTC market under the ticker symbol GLPYY.

R&D division
In December 2006 Galapagos acquired ProSkelia in Romainville, France, from ProStrakan via an all-share transaction. With ProSkelia, Galapagos obtained R&D operations and a product portfolio of products focused on musculoskeletal diseases (osteoporosis, cachexia and bone metastasis).

Galapagos has entered into long term alliances for the majority of its research programs with top ten pharma companies. These risk sharing alliances enable Galapagos to build a pipeline of more than 50 programs, based predominantly on proprietary targets that the Company has identified. Through this alliance strategy, Galapagos is eligible to receive approximately €3 billion in success-dependent milestone revenue plus up to double-digit royalties on commercial products.

Service division
In October 2005 Galapagos acquired BioFocus, a drug discovery company based in Saffron Walden, UK. In 2006, Galapagos acquired the drug discovery operations of Discovery Partners International and UK-based Inpharmatica Ltd. Galapagos acquired the structure-based drug discovery business of Sareum Holdings plc in 2008. These strategic acquisitions enable BioFocus to offer a full suite of target-to-candidate drug discovery products and services, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

In February 2010, Galapagos acquired Argenta's service operations. Together, Argenta and BioFocus form one of the world's largest drug discovery service organizations, with 350 employees, an estimated €70 M in annual turnover and significant profitability.
?
?